IP
Innate Pharma S.A.
IPHA · NASDAQ
$1.90 +0.53% (+$0.01)
1M -15.93%
Market Cap 156.3M €
P/E Ratio -
Div. Yield -
ROE 933.18%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 56.07x
P/FFO N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 63.58%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 1,764.51%
Op. margin 1,916.94%
FCF margin 1,823.01%
Quality
1 /100
Poor ROE 933.18%
ROA 78.44%
Asset turnover 0.04x
Debt
24 /100
High Int. coverage -110.77x
Current ratio 1.27x
Net debt/EBITDA N/A
Stability
28 /100
Unstable Rev. volatility 38.58%
EPS volatility 364.59%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na IPHA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jonathan E. Dickinson
Employees
163
Headquarters
Marseille